Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight

Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform a

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percen

Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 i

Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/down

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with

Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and rais

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powerin

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight

Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperfor

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the h

AMD: 15% | AMD To Power Meta AI Expansion With Up To 6 Gigawatts Of Instinct GPUs Under Multi Year A

Vir Biotechnology stock skyrockets after $335 million Astellas deal, strong prostate cancer data, an

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises th

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new data from the ongoing Phase 1 clinical tria

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of ex

Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintain

Vir Biotechnology, Inc. (NASDAQ:VIR) today provided key program updates, including new positive data

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) wit

– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.17) per share which missed the analy